243 related articles for article (PubMed ID: 29360440)
1. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
3. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
5. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
7. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
10. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
11. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
12. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
13. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
14. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
16. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
[TBL] [Abstract][Full Text] [Related]
18. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R
Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
